Verdiperstat decreased MPO activity and ROS levels in XDP‐treated SH‐SY5Y cells. (A) One‐way ANOVA revealed a significant effect of treatment ([F (2, 9) = 29.19], p = 0.0001) on MPO activity in SH‐SY5Y cells. Tukey's test revealed a significant increase in MPO activity in XDP treated cells compared with both vehicle (p = 0.0012) and XDP+verdiperstat treated cells (p = 0.0001). (B) Two‐way ANOVA revealed a significant effect of treatment ([F (4, 48) = 16.35], p < 0.0001), and time ([F (12, 48) = 31.68], p < 0.001) on ROS levels in SH‐SY5Y cells. As expected, ROS levels were increased in antimycin A treated cells compared with vehicle treatment (Tukey's test, p = 0.0003). Additionally, Tukey's test demonstrated a significant increase in ROS in XDP treated cells compared with both vehicle (p = 0.0014) and XDP+verdiperstat treated cells (p < 0.0001, respectively). **p < 0.01; ***p < 0.001; ****p < 0.0001.